Jounce Therapeutics Competitors and Similar CompaniesClear all

Jounce Therapeutics's competitors and similar companies include Personalis, Lyell, Triumvira, Immunai, Seagen and MetaStat.
Jounce Therapeutics
Jounce Therapeutics
Jounce Therapeutics is a clinical-stage immunotherapy company.
Personalis
Personalis
Personalis is a company specializing in cancer genomics.
Lyell
Lyell
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
Triumvira
Triumvira
Triumvira Immunologics is an immunotherapy company.
Immunai
Immunai
Immunai is a company that develops immune system technology.
Seagen
Seagen
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.
MetaStat
MetaStat
MetaStat, Inc. develops and commercializes diagnostic tests for risk of cancer metastasis, companion diagnostics and anti-metastatic drugs.
Founding Date
Founding Date
2013
Founding Date
2011
Founding Date
2018
Founding Date
2015
Founding Date
2018
Founding Date
1998
Founding Date
2010
Type
Type
Public
Type
Public
Type
Public
Type
Private
Type
Private
Type
Subsidiary
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Locations
Menlo Park, US HQ
Shanghai, CN
West Wickham, GB
Locations
South San Francisco, US HQ
Bothell, US
Seattle, US
Locations
Austin, US HQ
Hamilton, CA
Locations
New York, US HQ
Prague, CZ
Ness Ziona, IL
Tel Aviv, IL
Zurich, CH
Locations
Bothell, US HQ
Mississauga, CA
Hørsholm, DK
Rueil Malmaison, FR
München, DE
Milano, IT
Schiphol, NL
see more
Locations
Boston, US HQ
Employees
Employees
1302% increase
Employees
32538% increase
Employees
188
Employees
608% decrease
Employees
1563% increase
Employees
3,25622% increase
Employees
6
Valuation ($)
Valuation ($)
101.6 m
Valuation ($)
66.7 m
Valuation ($)
468.5 m
Valuation ($)
N/A
Valuation ($)
1.2 b
Valuation ($)
N/A
Valuation ($)
20.6 k
Twitter followers
Twitter followers
1.1 k
Twitter followers
3 k
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
1.1 k
Twitter followers
4.9 k
Twitter followers
325
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
6
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
1
Number of tweets (last 30 days)
11
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
1.5
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
4.2
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Employee Rating
Employee Rating
4.3
Employee Rating
3.7
Employee Rating
3.4
Employee Rating
4
Employee Rating
4.5
Employee Rating
4
Employee Rating
N/A

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$65m (FY, 2022)
Revenue (est.)
$84.7m (FY, 2022)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$2b (FY, 2022)
Revenue (est.)
$23.3k (FY, 2018)
Cost of goods
Cost of goods
N/A
Cost of goods
$51.7m (FY, 2022)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$410.1m (FY, 2022)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$13.4m (FY, 2022)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$1.6b (FY, 2022)
Gross profit
N/A
Net income
Net income
($50.9m) (FY, 2022)
Net income
($113.3m) (FY, 2022)
Net income
($183.1m) (FY, 2022)
Net income
N/A
Net income
N/A
Net income
($610.3m) (FY, 2022)
Net income
($3.2m) (FY, 2018)

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 55m (over 3 years ago)
Latest funding round
$ 215m (over 2 years ago)
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
$ 103m
Total funding raised
$ 75m
Total funding raised
N/A
Total funding raised
$ 55m
Total funding raised
$ 295m
Total funding raised
$ 164m
Total funding raised
$ 350k
For sources of this data, please see the company profile

View Company Profiles

Personalis
HQ
Menlo Park, US
Employees
325↑ 38% increase

Personalis is a company specializing in cancer genomics.

View company
Lyell
HQ
South San Francisco, US
Employees
188

Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.

View company
Triumvira
HQ
Austin, US
Employees
60↓ 8% decrease

Triumvira Immunologics is an immunotherapy company.

View company
Immunai
HQ
New York, US
Employees
156↑ 3% increase

Immunai is a company that develops immune system technology.

View company